April 15, 2025

Registration Opens for Access Insights Conference 2025: The Only Pharma Conference Covering the Full Commercialization Spectrum

Agenda Focuses on Balancing Patient Access and Net Revenue Optimization

Keynote Speaker Bill Roth Joins Industry Veterans, Practitioners, and Technologists

Philadelphia, PA, April 15, 2025 – IntegriChain, the leading provider of pharma revenue optimization technology and insights, today announced the opening of registration for Access Insights Conference 2025, co-hosted with Blue Fin Group. The conference, the only event dedicated to the full spectrum of pharmaceutical commercialization, will take place October 27-29, 2025, at The Mayflower Hotel, Autograph Collection, in Washington, DC. Registration is now available on the Access Insights Conference website.

Designed for commercial, operational, and financial executives and teams at pharmaceutical manufacturers, the conference delivers high-level strategic insights alongside practical, real-world solutions. Attendees will leave with a clear roadmap to navigate the next decade of commercialization success, gaining the knowledge needed to address evolving industry challenges from strategic pre-launch planning to operational execution that optimizes both patient access and net revenue.

“As pharmaceutical manufacturers confront increasing regulatory and pricing pressures, the industry’s top priority is achieving a sustainable balance between patient access and net revenue optimization,” said IntegriChain CEO Josh Halpern. “Success demands that commercial leaders align strategy, technology, and execution in unprecedented ways. Access Insights Conference 2025 brings together industry experts and executives to provide both strategic vision and actionable tactics to drive commercialization success and maximize net revenue for innovative therapies.”

Keynote and Industry Expertise

Headlining the event is Bill Roth, General Manager and Managing Partner of Blue Fin Group, a recognized expert in healthcare business model development. Roth’s keynote will address how chief commercial officers and access leaders can break the gross-to-net bubble by 2030. The conference will also feature a distinguished lineup of industry leaders, healthcare policy and financial experts, and seasoned practitioners offering insights into commercialization strategies across all pharmaceutical product archetypes, life cycles, and portfolios.

Conference Highlights

Executive Summit
The conference kicks off with Bill Roth’s keynote on breaking the gross-to-net bubble by 2030. Attendees will hear from influential panels on the latest healthcare policy shifts, market dynamics, and their impact on pricing and commercialization strategies. Industry leaders in market access will also share insights on navigating today’s most pressing challenges.

Expert Panels & Key Industry Trends
Sessions will explore three major industry shifts:

• The financial C-suite’s expanding role in commercialization and access
• The changing dynamics of retail pharmacy and cash-pay models
• How chief commercial officers will balance revenue and patient access over the next decade

Focused Content Tracks
Pricing, Policy, and Reimbursement. Topics include MFP readiness, navigating healthcare policy changes, transitioning from affordability programs, innovating GP modeling, making complex 340B financial decisions, and staying ahead of state price transparency requirements.

Data and Technology. Discussions will cover IRA and 340B operational readiness, evaluating SaaS vs. outsourcing strategies, optimizing distribution contracting, strengthening affordability program controls, leveraging AI/ML innovation, and maximizing data warehousing for commercial and access decision-making.

Business and Strategy. Sessions will address transforming net revenue access in Big Pharma, making pre-commercialization decisions, refining commercial data strategies, adapting to shifting stakeholder economics, and optimizing portfolio mix for long-term success.

For more information and to register, visit the Access Insights Conference website.

About Blue Fin Group, an IntegriChain Company
Blue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support life sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers–primarily those commercializing their first asset or large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit https://consultbfg.com/ or follow on LinkedIn.

About IntegriChain
IntegriChain is the leading provider of revenue optimization technology and insights for the Pharma industry. The company’s unique combination of data management, enterprise applications, consulting, and outsourcing helps manufacturers achieve better financial results by connecting commercial execution to net revenue. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Technology. IntegriChain is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.